Can-Fite BioPharma American Depositary Shares
CANF
8 hedge funds and large institutions have $1.06M invested in Can-Fite BioPharma American Depositary Shares in 2024 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 3 closing their positions.
66% more capital invested
Capital invested by funds: $638K → $1.06M (+$422K)
0% more ownership
Funds ownership: 0% → 0% (+0%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
11% less funds holding
Funds holding: 9 → 8 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$477K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$29.6K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$4.55K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$76.7K |
| 2 |
SIA
Schechter Investment Advisors
Birmingham,
Michigan
|
-$44.2K |
| 3 |
SHIM
Stone House Investment Management
Tunkhannock,
Pennsylvania
|
-$1.03K |
| 4 |
TWC
TD Waterhouse Canada
Toronto,
Ontario, Canada
|
-$54 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $850K | +$477K | +11,422 | +148% |
|
|
2
Morgan Stanley
New York
| $124K | -$76.7K | -1,837 | -40% |
|
3
RhumbLine Advisers
Boston,
Massachusetts
| $41K | – | – | – |
|
|
4
Citadel Advisors
Miami,
Florida
| $31.5K | +$29.6K | +709 | New |
|
5
Fifth Third Bancorp
Cincinnati,
Ohio
| $6.66K | – | – | – |
|
|
6
UBS Group
Zurich,
Switzerland
| $4.82K | +$4.55K | +109 | New |
|
7
National Bank of Canada
Montreal,
Quebec, Canada
| $1.25K | – | – | – |
|
8
Citigroup
New York
| $1.23K | – | – | – |
|
|
SIA
9
Schechter Investment Advisors
Birmingham,
Michigan
| – | -$44.2K | -1,004 | Closed |
|
|
SHIM
10
Stone House Investment Management
Tunkhannock,
Pennsylvania
| – | -$1.03K | -24 | Closed |
|
|
TWC
11
TD Waterhouse Canada
Toronto,
Ontario, Canada
| – | -$54 | -1 | Closed |
|
CANF Hedge Fund Activity: Q1 2024 in Review
8 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Can-Fite BioPharma American Depositary Shares (CANF) for Q1 2024, worth a combined $1.06M — up 66% from $638K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of CANF and 2 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 1 added.
The largest buyer was Armistice Capital, adding an estimated $477K. The largest seller was Morgan Stanley, cutting an estimated $76.7K.
- 8 institutional investors held Can-Fite BioPharma American Depositary Shares (CANF) as of Q1 2024, down from 9 in Q4 2023.
- Funds reported $1.06M of Can-Fite BioPharma American Depositary Shares stock for Q1 2024, up 66% quarter-over-quarter.
- 2 funds opened new Can-Fite BioPharma American Depositary Shares positions in Q1 2024 and 3 closed out, a net change of -1 holder.
- The largest Can-Fite BioPharma American Depositary Shares buyer in Q1 2024 was Armistice Capital, an estimated $477K added.
- The largest Can-Fite BioPharma American Depositary Shares seller in Q1 2024 was Morgan Stanley, an estimated $76.7K sold.
Based on aggregated 13F filings for Q1 2024.